American Society of Hirudotherapy

Identifying genes for neuron survival and axon outgrowth in Hirudo medicinalis

Research article published in Journal of anatomy (2004)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewGenomics & ProteomicsBlackshaw S et al. · Journal of anatomy, 2004

Abstract

We have studied the molecular basis of nervous system repair in invertebrate (Hirudo medicinalis) nerve cells. Unlike in mammals, neurons in invertebrates survive injury and regrow processes to restore the connections that they held before the damage occurred. To identify genes whose expression is regulated after injury, we have used subtractive probes, constructed from regenerating and non-regenerating ganglia from the leech Hirudo medicinalis, to screen cDNA libraries made from whole leech CNS or from identified microdissected neurons. We have identified genes of known or predicted function as well as novel genes. Known genes up-regulated within hours of injury and that are widely expressed in invertebrate and mammalian cells include thioredoxin and tubulin. Other known genes, e.g. Cysteine Rich Intestinal Protein (CRIP), have previously been identified in mammalian cells though not in regenerating adult neurons. Two regulated genes identified, myohemerythrin and the novel protein ReN3 are exclusively expressed in invertebrates. Thus our approach has enabled us to identify genes, present in a neuron of known function, that are up- and down-regulated within hours of axotomy, and that may underpin the intrinsic ability of invertebrate neurons to survive damage and initiate regrowth programmes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAnimalsAxonsCell SurvivalGene Expression RegulationGene LibraryLeechesModels, AnimalNerve RegenerationNeuronsOligonucleotide Array Sequence Analysis

Summary

Using subtractive cDNA screening of regenerating versus non-regenerating Hirudo medicinalis ganglia, this study identifies injury-regulated genes including thioredoxin and tubulin, plus invertebrate-specific candidates such as myohemerythrin and ReN3, possibly underlying the intrinsic ability of leech neurons to regrow after axotomy.

Why This Matters for Hirudotherapy

This study examined the molecular basis of nervous system repair in Hirudo medicinalis, using subtractive probes from regenerating and non-regenerating ganglia to screen cDNA libraries and identify genes—including thioredoxin, tubulin, CRIP, myohemerythrin, and a novel protein ReN3—that are up- or down-regulated within hours of axotomy in identified leech neurons. This characterizes the fundamental molecular biology of the medicinal leech, specifically the gene expression programs that may underpin this species' notable capacity to survive neuronal injury and regenerate neural processes. However, the connection to hirudotherapy is indirect: the study investigates the leech's own neurobiology rather than salivary secretome components or therapeutic applications, and its findings concern basic comparative neurobiology with no direct clinical implications for leech therapy practice.

Citation

Reference (Vancouver style)

Blackshaw SE, Babington EJ, Emes RD, Malek J, Wang WZ. Identifying genes for neuron survival and axon outgrowth in Hirudo medicinalis. J Anat. 2004;204(1):13-24. doi:10.1111/j.1469-7580.2004.00260.x. PMID: 14690474

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.